文献速递甲状腺疾病

BRAF靶向治疗后手术与BRAFV600E突变型甲状腺未分化癌生存改善相关:单中心回顾性队列研究

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.
PubMed 文献 · Thyroid · 2023-03-20

单中心回顾性队列研究纳入2017至2021年57例BRAFV600E突变型甲状腺未分化癌患者,接受BRAF靶向治疗至少1个月。新辅助BRAF靶向治疗后手术组(n=32)12个月总生存率93.6%、无进展生存率84.4%;术后BRAF靶向治疗组(n=12)分别为74.1%和50%;未手术组(n=13)分别为38.5%和15.4%。

要点

  • 新辅助BRAF靶向治疗后手术组12个月总生存率93.6%,无进展生存率84.4%。
  • 未手术组12个月总生存率38.5%,无进展生存率15.4%。
  • 新辅助BRAF靶向治疗缩小肿瘤、降低手术范围和手术并发症评分。

核心结论

  • 新辅助BRAF靶向治疗缩小手术范围并降低手术并发症。
  • 在承认潜在选择偏倚的前提下,BRAF靶向治疗后手术组的12个月总生存率似乎高于未手术组,但与术后BRAF靶向治疗组无显著差异。
  • 新辅助BRAF靶向治疗后手术组的无进展生存率似乎高于其他两组。
  • 这些有希望的结果应在前瞻性临床试验中确认。

研究设计与样本

  • 单中心回顾性队列研究,2017至2021年在德克萨斯州一家三级癌症中心开展。
  • 纳入57例连续BRAFV600E突变型甲状腺未分化癌且接受BRAF靶向治疗至少1个月的患者。
  • 主要结局为总生存期和无进展生存期。

主要发现

  • 全部患者为IVB期(35%)或IVC期(65%)甲状腺未分化癌。
  • 约70%接受BRAF靶向治疗的患者最终行残留病灶手术切除。
  • 新辅助BRAF靶向治疗后手术组(n=32)12个月总生存率93.6%[CI 84.9-100],无进展生存率84.4%[CI 71.8-96.7]。
  • 术后BRAF靶向治疗组(n=12)12个月总生存率74.1%[CI 48.7-99.5],无进展生存率50%[CI 21.7-78.3]。
  • 未手术组(n=13)12个月总生存率38.5%[CI 12.1-64.9],无进展生存率15.4%[CI 0-35.0]。

关键数值与推荐

  • 新辅助BRAF靶向治疗缩小肿瘤大小、手术范围和手术并发症评分。
  • 亚组分析提示手术标本中任何残留甲状腺未分化癌与更差的12个月总生存率和无进展生存率相关:残留组总生存率83.3%[CI 62.6-100]、无进展生存率61.5%[CI 35.1-88],病理完全缓解组总生存率和无进展生存率均为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文承认存在潜在选择偏倚。
  • 这些有希望的结果应在前瞻性临床试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The aim of this study was to describe the oncologic outcomes of patients with BRAFV600E-mutated anaplastic thyroid cancer (ATC) who had neoadjuvant BRAF-directed therapy with subsequent surgery. For context, we also reviewed patients who received BRAF-directed therapy after surgery, and those who did not have surgery after BRAF-directed therapy. Methods: This was a single-center retrospective cohort study conducted at a tertiary care cancer center in Texas from 2017 to 2021. Fifty-seven consecutive patients with BRAFV600E-mutated ATC and at least 1 month of BRAF-directed therapy were included. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Results: All patients had stage IVB (35%) or IVC (65%) ATC. Approximately 70% of patients treated with BRAF-directed therapy ultimately had surgical resection of residual disease. Patients who had neoadjuvant BRAF-directed therapy followed by surgery (n = 32) had 12-month OS of 93.6% [confidence interval (CI) 84.9-100] and PFS of 84.4% [CI 71.8-96.7]. Patients who had surgery before BRAF-directed therapy (n = 12) had 12-month OS of 74.1% [CI 48.7-99.5] and PFS of 50% [CI 21.7-78.3]. Finally, patients who did not receive surgery after BRAF-directed therapy (n = 13) had 12-month OS of 38.5% [CI 12.1-64.9] and PFS of 15.4% [CI 0-35.0]. Neoadjuvant BRAF-directed therapy reduced tumor size, extent of surgery, and surgical morbidity score. Subgroup analysis suggested that any residual ATC in the surgical specimen was associated with significantly worse 12-month OS and PFS (OS = 83.3% [CI 62.6-100], PFS = 61.5% [CI 35.1-88]) compared with patients with pathologic ATC complete response (OS = 100%, PFS = 100%). Conclusions: We observed that neoadjuvant BRAF-directed therapy reduced extent of surgery and surgical morbidity. While acknowledging potential selection bias, the 12-month OS rate appeared higher in patients who had BRAF-directed therapy followed by surgery as compared with BRAF-directed therapy without surgery; yet, it was not significantly different from surgery followed by BRAF-directed therapy. PFS appeared higher in patients treated with neoadjuvant BRAF-directed therapy relative to patients in the other groups. These promising results of neoadjuvant BRAF-directed therapy followed by surgery for BRAF-mutated ATC should be confirmed in prospective clinical trials.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Zhao X, Wang JR, Dadu R, et al. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023. PMID: 36762947. doi:10.1089/thy.2022.0504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。